Successful use of clopidogrel for cerebrovascular accident in a patient with suspected ticlopidine-induced hepatotoxicity

Annals of Pharmacotherapy

Volumn 33, Issue 9, 1999, Pages 939-941

  Zeolla, Mario M ^a   Carson, John J ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b St Peter's Hospital Albany   (United States)

Author keywords

Clopidogrel; Hepatotoxicity; Ticlopidine

Indexed keywords

ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; CONJUGATED ESTROGEN; DONEPEZIL; FUROSEMIDE; INSULIN; MEDROXYPROGESTERONE; QUINAPRIL;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG INDUCED DISEASE; FEMALE; GERIATRIC PATIENT; HEPATOMEGALY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIVER FUNCTION TEST; LIVER TOXICITY; PRIORITY JOURNAL;

AGED; CEREBROVASCULAR DISORDERS; FEMALE; HUMANS; LIVER DISEASES; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0032826443     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18435     Document Type: Article

References (19)

1. Product information. Ticlid (ticlopidine). Mississauga, Ontario, Canada: Syntex, 1993.
2. Product information. Plavix (clopidogrel). New York, NY: Sanofi Pharmaceuticals, Inc., 1997.
3. Cassidy LJ, Schuster BG, Halparin LS. Probable ticlopidine-induced cholestatic hepatitis. Ann Pharmacother 1995;29:30-2.
4. Ruiz-Valvarde P, Zafon C, Segarra A, Ribera R, Piera L. Ticlopidine-induced granulomatous hepatitis (letter). Ann Pharmacother 1995;29:633-4.
5. Klepser TB, Jogerst GJ. Ticlopidine-induced elevated liver enzymes. Pharmacotherapy 1997;17:819-21.
6. Greaney JJ Jr, Hess DA, Mahoney C. Ticlopidine-induced cholestatic jaundice (letter). Clin Pharm 1993;12:398-9.
7. Roy L, Plante MA, Perreault H, Biron P. Cholestatic hepatitis: ticlopidine suspected (letter). Therapie 1995;50:593-4.
8. Martínez Pérez-Balsa A, De Arce A, Castiella A, López P, Ruibal M, Ruiz-Martínez J, et al. Hepatotoxicity due to ticlopidine. Ann Pharmacother 1998;32:1250-1.
9. Mammarella A, Paoletti V, Moroni C, Cassone R. Ittero colestatico da ticlopidina. Clin Ter 1991;138:45-6.
10. Deschamps JP, Lassegue A, Ottignon Y, Vuitton D, Allemand H, Carayon P, et al. Ictere cholestatique associe a la prise de ticlopidine: a propos des deux premiers cas. Gastroenterol Clin Biol 1982;6:595-6.
11. Biour M, Toussaint P, Duhamel G, Canuel C, Krulick M, Calmus Y. Ticlopidine: atteintes sanguines et hepatiques? Therapie 1982;37:217-24.
12. Eugene C, Lefebvre JF, Gury B, Quevauvilliers J. Hespatite cholestatique: role vraisemblable de la ticlopidine. Sem Hôp Paris 1983;59:2923-4.
13. Miyahara K, Kasahara N, Kondo Y, Imai Y, Matuzaki F. Changes in plasma lipids and abnormal lipoproteitis in a patient with drug-induced cholestatic hepatitis. Jpn J Med 1991;30:354-9.
14. Product information. Aricept (donepezil). New York, NY: Roerig Division of Pfizer Inc., 1996.
15. Rogers SL, Friedhoff LT, and the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
16. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-45.
17. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998;158:577-84.
18. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
19. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;76:939-43.